GE Healthcare Technologies Inc (GEHC) Investment Analysis:
1. Executive Summary:
GE Healthcare Technologies Inc. (GEHC) stands as a premier global provider of medical technology, pharmaceutical diagnostics, and digital solutions, operating as an independent entity since its strategic spin-off from General Electric in early 2023.[1, 2] With a corporate legacy spanning over 130 years, the company serves as a critical infrastructure layer for the global healthcare industry, serving approximately one billion patients annually through a massive installed base of roughly five million units across medical imaging, ultrasound, and patient monitoring modalities.[2, 3, 4] The company operates a diversified business model that generates revenue through the sale of high-complexity medical hardware, recurring service contracts, and high-margin consumable pharmaceutical diagnostics, providing a resilient mix of capital expenditure-driven and recurring cash flows.[5, 6]
The company's operational structure is organized into four primary reporting segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx), though recent strategic realignments have seen the consolidation of Imaging and AVS into a singular Advanced Imaging Solutions (AIS) segment to accelerate the adoption of cloud-enabled and AI-driven diagnostics.[7, 8, 9] GEHC maintains a strong global footprint, with the United States and Canada representing the largest revenue contributor at approximately 40%, followed by the Europe, Middle East, and Africa (EMEA) region at roughly 34%, and significant emerging market exposure, particularly in China.[5, 6]
| Revenue Category |
Contribution (%) |
Primary Drivers |
| Product Sales |
~66% |
Sales of CT, MRI, Ultrasound, and Life Support hardware.[6] |
| Service Revenue |
~34% |
Multi-year maintenance contracts and high customer capture rates.[6, 7] |
| Recurring Revenue |
~50% (Target 60%) |
Contrast media, service contracts, and growing SaaS/SaaS subscriptions.[10] |
The primary customer base for GEHC includes large public and private hospital networks, independent diagnostic imaging centers, and clinical research institutions.[11, 12, 13] Customers consistently select GEHC over domestic and international alternatives due to the company's "D3 strategy"—an integrated approach that combines smart devices, diagnostics drugs, and digital solutions to facilitate precision care.[4, 10] This ecosystem advantage, coupled with a record $21.8 billion backlog and a 55% "New Product Introduction" (NPI) vitality rate, ensures that GEHC remains the default partner for hospital systems undergoing digital transformation and equipment refresh cycles.[6, 10, 14]
GLOBAL PRECISION LEADER
2. Business Drivers & Strategic Overview:
The strategic trajectory of GE Healthcare is defined by a pivot from a legacy hardware manufacturer to a provider of holistic "Precision Care" clinical ecosystems.[4, 5] This transition is underpinned by massive internal investments in R&D and aggressive M&A activity focused on the software layer of the clinical workflow.[10, 15]
Product and Service Detail
GEHC’s portfolio spans the entire patient journey from early screening to treatment monitoring. The hardware business is increasingly being treated as the "enabling platform" for high-margin software and service monetization.
- Advanced Imaging Solutions (AIS): This segment represents the core engine of the company, delivering Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Molecular Imaging, and X-ray systems.[5, 8] Key products include the Revolution product line in CT and the SIGNA MR scanners, which are increasingly equipped with deep-learning reconstruction tools like AIR Recon DL to improve image quality and reduce scan times.[4, 7]
- Pharmaceutical Diagnostics (PDx): This highly profitable segment produces contrast media used in medical imaging, such as Omnipaque and Visipaque, as well as molecular imaging agents like the newly launched PET tracer, Flyrcado.[4, 16] These products are essential consumables, creating a high-frequency recurring revenue stream that is largely decoupled from hardware capital cycles.[6, 17]
- Ultrasound and Patient Care Solutions: GEHC is a global leader in ultrasound, particularly in the women’s health and cardiovascular segments through the Voluson and Vivid platforms.[4, 5] The Patient Care Solutions (PCS) unit provides monitoring, anesthesia, and maternal-infant care systems, which are critical for hospital-wide clinical integration.[5, 8]
Moat Analysis
GEHC possesses a formidable economic moat categorized by high switching costs, scale advantages, and significant intellectual property barriers.
- Installed Base and Switching Costs: With approximately 5 million units globally, hospital systems are deeply locked into GEHC’s technical architecture.[3, 4] Transitioning to a different OEM involves not only the capital cost of the machines but also the massive labor expense of retraining radiologists and technologists, along with potential compatibility issues with legacy data.[5, 17]
- Intellectual Property and AI Leadership: GEHC has secured 115 FDA authorizations for AI-enabled medical devices, more than any other medtech company, establishing a "data moat" where its software provides superior diagnostic accuracy that competitors struggle to match.[4, 10]
- Scale and Distribution: The company’s global workforce of 54,000 enables a localized service model that ensures high uptime for its machines—a critical metric for hospital profitability.[5, 18] Smaller rivals lack the logistical network required to compete for large-scale enterprise deals.[5, 13]
- Ecosystem Synergy (D3): By manufacturing both the imaging hardware and the pharmaceutical tracers required for high-definition scans, GEHC creates a "one-stop-shop" ecosystem that simplifies hospital procurement and clinical delivery.[4, 17]
TAM / Market Opportunity Analysis
The total addressable market (TAM) for medical imaging and diagnostics is projected to expand significantly, driven by demographic shifts and the integration of AI.
| Market Segment |
2025-2026 Est. Size ($B) |
Projected CAGR (%) |
Key Drivers |
| Global Medical Imaging |
$46.0B - $48.3B |
4.7% - 6.7% |
Aging populations, chronic disease rise.[11, 19, 20] |
| Ultrasound Device Market |
$9.8B |
5.6% |
Non-invasive diagnosis, point-of-care.[20] |
| Digital Solutions / AI |
$110B+ (Long-term TAM) |
N/A |
Cloud-enabled ecosystems, SaaS adoption.[21] |
Competitive Landscape
The industry is characterized by a "Big Three" structure, with GEHC consistently maintaining or gaining share in core areas like molecular imaging and ultrasound while facing stiff competition in high-end hardware.
- Siemens Healthineers: GEHC’s most formidable rival, particularly in high-end CT and MRI.[5] Siemens is leveraging its acquisition of Varian to dominate end-to-end oncology care, though GEHC is countering this through its strength in molecular imaging.[5, 17]
- Philips Healthcare: Strong in patient monitoring but currently weakened by large-scale respiratory product recalls, which have damaged its brand and allowed GEHC to win "share of mind" among hospital procurement officers.[5, 17]
- Emerging Challengers (Fujifilm / Mindray): These firms compete aggressively on price in mid-tier ultrasound and emerging markets.[5, 22] GEHC is responding by localizing manufacturing ("China-for-China") and introducing high-value NPIs to maintain its premium positioning.[5, 10]
Strategically, GEHC appears to be holding its ground in developed markets while using its PDx business as a growth wedge into molecular medicine, positioning it favorably against hardware-only competitors.[5, 17]
PRECISION ECOSYSTEM DOMINANCE
3. Financial Performance & Valuation:
GE Healthcare reported its First Quarter 2026 results on April 29, 2026, which reflected a complex operating environment where resilient top-line growth was offset by unexpected macroeconomic headwinds.[9, 16, 23]
Latest Quarterly Performance (Q1 2026)
The company reported total revenues of $5.131 billion, a 7.4% year-over-year increase, narrowly beating the Zacks consensus estimate of $5.05 billion.[15, 24, 25] Organic revenue growth was 2.9%, demonstrating healthy underlying demand despite supply chain frictions.[9, 14]
However, the bottom line was pressured significantly:
* Adjusted EPS: $0.99, missing the consensus estimate of $1.07 by $0.08.[23, 26]
* GAAP EPS: $0.85, down 30.9% year-over-year from $1.23.[14, 24]
* Adjusted EBIT Margin: 13.5%, a decline from 15.0% in the prior-year period.[7, 14]
| Metric |
Q1 2026 Actual |
Q1 2025 Actual |
Change (%) |
| Revenue |
$5,131M |
$4,777M |
+7.4% [15] |
| Net Income |
$389M |
$564M |
-31.0% [14] |
| Adjusted EBIT |
$691M |
$715M |
-3.4% [16] |
| Free Cash Flow |
$112M |
$99M |
+13.1% [9, 27] |
Management Commentary and Guidance Revisions
During the earnings call, CEO Peter Arduini and CFO Jay Saccaro highlighted that while demand remains robust—evidenced by a record $21.8 billion backlog—the company encountered a $250 million inflationary shock during the quarter.[7, 9] This includes a $100 million surge in memory chip costs, $100 million in oil/freight increases, and $50 million in commodity pricing for metals like tungsten.[7, 28] Furthermore, a discrete supplier recall in the PDx segment (now resolved) created a $0.05 drag on EPS.[7, 9, 14]
Consequently, management lowered full-year 2026 guidance:
* Adjusted EPS: Reduced to $4.80–$5.00 (from $4.95–$5.15).[9, 14, 24]
* Adjusted EBIT Margin: Reduced to 15.4%–15.7% (from 15.8%–16.1%).[9, 14]
* Free Cash Flow: Lowered to approximately $1.6 billion (from $1.7 billion).[9, 14]
The market reacted negatively to the guidance cut, with shares plunging approximately 8.9% in pre-market trading and continuing to fall toward the $59.25 level—approaching a 52-week low.[26, 28]
Valuation Analysis and Financial Drivers
The most critical financial drivers for GEHC valuation are the conversion of its massive backlog and the expansion of margins through its "Heartbeat" lean business system.[4, 29]
- Sales Growth: GEHC has maintained an annual revenue growth rate of approximately 4% over the past five years.[30, 31] For 2026, analysts forecast revenue reaching approximately $22.09 billion, representing a 7.1% year-over-year increase as the Intelerad acquisition integrates.[32]
- Margin Expansion: Despite the Q1 dip, management expects a margin "step up" in the second half of 2026 as pricing actions take hold.[7] The company targets a long-term adjusted EBIT margin in the high teens as software becomes a larger mix of sales.[10]
- Capital Structure: GEHC ended Q1 with $10.13 billion in debt following the financing for the $2.3 billion Intelerad acquisition.[15] With a Debt-to-Equity ratio of 0.91, the balance sheet remains resilient, and the company continues to repurchase shares, including $100 million in Q1.[27, 33]
- Valuation Multiples: Following the earnings crash, GEHC trades at a forward P/E of roughly 12.0x–12.5x based on the low end of 2026 guidance ($4.80 EPS).[26, 34] This represents a significant valuation gap compared to a peer average near 34x, suggesting the stock is trading at a steep discount to its intrinsic value of approximately $91–$100.[35]
UNDERVALUED SCALE ADVANTAGE
4. Risk Assessment & Macroeconomic Considerations:
Investing in GEHC requires navigating a multifaceted risk landscape that includes geopolitical trade barriers, commodity volatility, and intense competitive pressures.
Execution and Strategic Risks
- Backlog Conversion Delays: GEHC’s "revenue visibility" is high due to its $21.8 billion backlog, but the conversion into actual revenue is often delayed by supply chain friction and hospital facility readiness.[9, 36] Any further slowdown in this conversion cycle would impede organic growth targets.
- M&A Integration: The $2.3 billion acquisition of Intelerad is a major bet on a SaaS-heavy imaging ecosystem.[15, 28] Integration failures or higher-than-expected dilution could weigh on the 2027 accretion targets.[7]
- China Exposure: China represents a critical but increasingly risky market. Government-mandated "Volume-Based Procurement" (VBP) could squeeze margins on standard hardware, while geopolitical tensions could favor domestic champions like Mindray.[5, 28]
Competitive and Industry Structure Risks
- Price Erosion: In the mid-tier and portable ultrasound segments, challengers like Fujifilm and Mindray are competing aggressively on price, potentially eroding GEHC’s market share in emerging markets.[5, 13]
- Technological Displacement: While GEHC leads in AI authorizations, tech giants like NVIDIA or Google Health could disrupt the medical software stack, forcing GEHC into lower-margin platform alliances rather than owning the end-to-end diagnostic software.[5]
Macroeconomic Sensitivities
- Tariff Volatility: GEHC is highly exposed to trade policy, incurring roughly $245 million in tariff costs in 2025 and $90 million in Q1 2026.[10, 15, 37] While the company is seeking refunds, a continuation of current trade regimes acts as a permanent tax on its hardware margins.[9, 28]
- Input Cost Inflation: The Q1 2026 experience showed that even a minor spike in oil, freight, or memory chip prices can wipe out hundreds of millions in profit, as medical hardware pricing is often locked in multi-year enterprise deals that lack flexible price escalators.[7, 28]
Warning Signs and Long-Term Thesis Damage
- Early Warning Sign: A book-to-bill ratio falling below 1.0x for consecutive quarters or a persistent decline in the organic revenue of the Patient Care Solutions (PCS) segment.[9, 36]
- Long-Term Damage: A systemic product failure or a major regulatory setback for the "innovation cycle"—specifically the LUMINA manganese tracer trial—would invalidate the company’s high-margin "Precision Care" growth story.[38, 39]
MACRO MARGIN PRESSURE
5. 5-Year Scenario Analysis:
The following scenario analysis models GEHC's trajectory through 2031, using a current share price of $59.25.[26, 40]
Base Case (Probability: 55%)
In this scenario, GEHC successfully converts its record backlog and mitigates inflation through the "Heartbeat" lean system.
* Financial Assumptions: Revenue grows at a 4.25% CAGR to ~$25.3 billion.[17, 32] Adjusted EBIT margins expand from 15.5% to 18.5% as the service/SaaS mix increases.[10, 32]
* Earnings: EPS reaches $7.25 by 2031.[41]
* Valuation Bridge: Hospital systems continue upgrading legacy systems; Intelerad becomes accretive by 2027; share count reduced by ~2% annually via buybacks.[7, 29]
* Exit Multiple: 17x P/E, reflecting a more stable and high-margin recurring revenue profile.[35]
* 5-Year Share Price: $123.25.
High Case (Probability: 20%)
The "Precision Care" cycle accelerates with breakthrough FDA approvals for molecular agents and AI adoption.
* Financial Assumptions: Revenue grows at a 6.5% CAGR to ~$28.4 billion.[11, 42] EBIT margins reach 22.0% on the success of mangaciclanol and photon-counting CT.[10, 38]
* Earnings: EPS reaches $10.15.[32]
* Valuation Bridge: GEHC becomes the dominant "Clinical OS" provider; rapid expansion in Asia-Pacific outpaces industry averages.[5, 11]
* Exit Multiple: 22x P/E, catching up to premium medtech peers.[35]
* 5-Year Share Price: $223.30.
Low Case (Probability: 25%)
Protracted trade wars and fierce competition in China lead to stagnant growth and margin compression.
* Financial Assumptions: Revenue grows at a 1.2% CAGR to ~$21.9 billion.[31, 32] EBIT margins remain stuck at 14.5% due to price wars in ultrasound and imaging.[5, 14]
* Earnings: EPS remains flat at ~$4.90.[9, 14]
* Valuation Bridge: Backlog conversion remains lumpy; capital returns are suspended to maintain debt covenants; market views GEHC as a "commodity hardware" play.[5, 36]
* Exit Multiple: 11x P/E.[28, 34]
* 5-Year Share Price: $53.90.
5-Year Scenario Summary
| Scenario |
Year 5 Revenue |
Margin Assumption |
P/E Multiple |
Current Price |
Implied Price |
5-Year Return |
Annualized |
Probability |
| High |
$28.4B |
22.0% |
22x |
$59.25 |
$223.30 |
+276.9% |
30.4% |
20% |
| Base |
$25.3B |
18.5% |
17x |
$59.25 |
$123.25 |
+108.0% |
15.8% |
55% |
| Low |
$21.9B |
14.5% |
11x |
$59.25 |
$53.90 |
-9.0% |
-1.9% |
25% |
Weighted Average Price Target: $125.90
COMPELLING REVALUATION POTENTIAL
6. Qualitative Scorecard:
The scorecard rates GEHC across ten key dimensions on a scale of 1 to 10.
| Metric |
Score |
Narrative |
| Management Alignment |
8 |
CEO Peter Arduini’s compensation ($18.6M) is 93% performance-based. Rigorous stock ownership and clawback policies are in place.[43, 44] |
| Revenue Quality |
7 |
Improving as the company moves toward 60% recurring revenue, though still reliant on cyclical hardware sales.[6, 10] |
| Market Position |
9 |
#1 in Ultrasound and a global "Big Three" player in imaging. Strong brand trust relative to competitors like Philips.[5, 17] |
| Growth Outlook |
6 |
Solid in PDx and AI, but muted overall by large scale and macroeconomic headwinds in hardware.[6, 14] |
| Financial Health |
7 |
Net leverage is manageable (Debt/Equity 0.91), with strong access to $3.5B in liquidity.[15, 33] |
| Business Viability |
9 |
High durability. Medical diagnostics are essential healthcare infrastructure; high switching costs provide a deep moat.[4, 17] |
| Capital Allocation |
8 |
Disciplined focus on R&D ($1.2B+), strategic tuck-in M&A, and returning capital to shareholders.[10, 29] |
| Analyst Sentiment |
5 |
Currently a consensus "Hold" following the Q1 2026 guidance cut and profit miss.[26, 33, 40] |
| Profitability |
6 |
Pressured in the short term (13.5% Q1 margin), needing strong H2 execution to reach annual targets.[7, 14] |
| Track Record |
7 |
Strong performance in first two years post-spin, though Q1 2026 represents a notable execution "stumble".[4, 10] |
Blended Qualitative Score: 7.2/10
DURABLE INSTITUTIONAL ASSET
7. Conclusion & Investment Thesis:
GE Healthcare Technologies Inc. represents a fundamentally strong, industry-leading business currently trading at a "macro-discount." The primary investment thesis relies on the company’s transition into a high-margin clinical software and diagnostics provider, a journey currently masked by the noisy impact of tariffs and inflationary shocks.[4, 5, 17]
The record $21.8 billion backlog provides a solid floor for valuation, ensuring multi-year revenue visibility even in a slowing economy.[9, 14, 28] The current Q1 2026 profit miss should be viewed as a transitory event driven by temporary commodity spikes and a resolved supplier issue, rather than a degradation of the core competitive moat.[7, 9] Furthermore, the company's leading position in AI authorizations and the strategic acquisition of Intelerad position it to capture the most profitable segment of the healthcare value chain: the clinical data ecosystem.[5, 10, 15]
Risks are concentrated in trade policy and execution within the China market, but these are largely reflected in the current compressed valuation multiples.[5, 28, 35] For professional investors, the current entry point near 52-week lows offers a compelling risk-reward profile for an asset with essential infrastructure status in the global healthcare market.[26, 28, 35]
TEMPORARY MARGIN DISLOCATION
8. Technical Analysis, Price Action & Short-Term Outlook:
The share price is in a clear bearish trend, currently at $59.25 and trading well below its 50-day ($75.37) and 200-day ($76.81) moving averages.[40, 45] The 13% single-day crash following the Q1 2026 results has triggered heavy volume and a "Hold" consensus among technical analysts.[26, 28, 45] The short-term outlook is negative until the stock finds a technical floor and management confirms progress on H2 margin mitigation.[7, 46]
OVERSOLD TECHNICAL STANCE
- Investor FAQs | GE HealthCare, https://investor.gehealthcare.com/resources/investor-faqs/
- GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth, https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-announces-executive-team-and-operational-updates
- GE HealthCare Investor Relations, https://investor.gehealthcare.com/
- 2025 Annual Report - GE HealthCare Investor Relations, https://investor.gehealthcare.com/static-files/4da76f4a-b4a2-46b9-8217-e7e082d79bcd
- What Is the Competitive Landscape of GE Healthcare? - Business Model Canvas Templates, https://businessmodelcanvastemplate.com/blogs/competitors/ge-healthcare-competitive-landscape
- Investment analysis of GE HealthCare Technologies Inc - Freedom24, https://freedom24.com/ideas/details/21153
- GE HealthCare (GEHC) Q1 2026 Earnings Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/04/29/ge-healthcare-gehc-q1-2026-earnings-transcript/
- 1Q 2026 Earnings Presentation - GE HealthCare Investor Relations, https://investor.gehealthcare.com/static-files/ef435a1d-8997-4ee9-93a2-7a378efd7ca9
- GE HealthCare reports first quarter 2026 financial results, https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-reports-first-quarter-2026-financial-results
- 4Q and Full Year 2025 Earnings Presentation - GE HealthCare Investor Relations, https://investor.gehealthcare.com/static-files/2c839b7e-8db0-4b22-b00a-eba9e20f6168
- Medical Imaging Market Size, Trends & Forecast 2026–2035, https://www.gminsights.com/industry-analysis/medical-imaging-market
- Comprehensive Review of Medical Imaging Devices Growth Potential, https://www.marketreportanalytics.com/reports/medical-imaging-devices-45817
- Diagnostic Equipment Trends and Forecast 2025-2033 - Market Report Analytics, https://www.marketreportanalytics.com/reports/diagnostic-equipment-46106
- GE HealthCare (Nasdaq: GEHC) posts Q1 2026 results and lowers profit outlook, https://www.stocktitan.net/sec-filings/GEHC/8-k-ge-health-care-technologies-inc-reports-material-event-269af84f98b0.html
- GE HealthCare (NASDAQ: GEHC) grows Q1 sales, closes $2.3B Intelerad deal - Stock Titan, https://www.stocktitan.net/sec-filings/GEHC/10-q-ge-health-care-technologies-inc-quarterly-earnings-report-8a8866a1ca4f.html
- GEHC posts mixed Q1 2026 financial results - AuntMinnie, https://www.auntminnie.com/industry-news/market-analysis/news/15823638/ge-healthcare-gehc-posts-mixed-q1-2026-financial-results
- GE HealthCare (GEHC): The Precision Sentinel Braces for a High-Tech Margin Duel, https://simplywall.st/community/narratives/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/nbgms61f-ge-healthcare-gehc-the-precision-sentinel-braces-for-a-high-tech-margin-duel
- GE HealthCare management to present at upcoming investor conferences - April 27, 2026, https://www.biospace.com/press-releases/ge-healthcare-management-to-present-at-upcoming-investor-conferences-april-27-2026
- Medical Imaging Market Size, Share | Global Demand [2035] - Business Research Insights, https://www.businessresearchinsights.com/market-reports/medical-imaging-market-120795
- Ultrasound Device Market Competitive Analysis Report 2025: - GlobeNewswire, https://www.globenewswire.com/news-release/2026/01/28/3227816/28124/en/ultrasound-device-market-competitive-analysis-report-2025-key-players-company-profiles-strategic-developments-mergers-product-innovations-revenue-insights-and-future-forecasts-to-2.html
- 44th Annual J.P. Morgan Healthcare Conference, https://investor.gehealthcare.com/static-files/2b0e1d60-769b-4185-8403-25ac81b2dabe
- Philips Ultrasound Market Share | Key Drivers 2026, https://www.6wresearch.com/market-takeaways-view/philips-ultrasound-market-share
- GE HEALTHCARE TECHNOLOGIES ($GEHC) Releases Q1 2026 Earnings, https://www.quiverquant.com/news/GE+HEALTHCARE+TECHNOLOGIES+%28%24GEHC%29+Releases+Q1+2026+Earnings
- GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines - TradingView, https://www.tradingview.com/news/zacks:f703a4576094b:0-gehc-q1-earnings-miss-estimates-revenues-beat-net-margin-declines/
- GE HealthCare (GEHC) Reports Q1 Earnings: What Key Metrics Have to Say - April 29, 2026 - Zacks.com, https://www.zacks.com/stock/news/2910672/ge-healthcare-gehc-reports-q1-earnings-what-key-metrics-have-to-say
- GE HealthCare Technologies (NASDAQ:GEHC) Posts Earnings Results - MarketBeat, https://www.marketbeat.com/instant-alerts/ge-healthcare-technologies-nasdaqgehc-posts-earnings-results-2026-04-29/
- GE HealthCare reports first quarter 2026 financial results - BioSpace, https://www.biospace.com/press-releases/ge-healthcare-reports-first-quarter-2026-financial-results
- GE HealthCare Q1 2026 slides: inflation pressures cut profit outlook - Investing.com, https://www.investing.com/news/company-news/ge-healthcare-q1-2026-slides-inflation-pressures-cut-profit-outlook-93CH-4645735
- GE HealthCare reports fourth quarter and full year 2025 financial results, https://investor.gehealthcare.com/static-files/032483bd-b163-4456-87f8-8a03a0843e1e
- GE HealthCare Technologies Revenue 2020-2025 | GEHC - Macrotrends, https://www.macrotrends.net/stocks/charts/GEHC/ge-healthcare-technologies/revenue
- GE HealthCare Technologies (NasdaqGS:GEHC) - Earnings & Revenue Performance, https://simplywall.st/stocks/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/past
- GE HEALTHCARE TECHNOLOGY (GEHC) Forecast, Price Target & Analyst Ratings, https://www.chartmill.com/stock/quote/GEHC/analyst-ratings
- GE HealthCare Technologies (NASDAQ:GEHC) Sets New 12-Month Low Following Weak Earnings - MarketBeat, https://www.marketbeat.com/instant-alerts/ge-healthcare-technologies-nasdaqgehc-sets-new-12-month-low-following-weak-earnings-2026-04-29/
- BTIG Research Issues Pessimistic Forecast for GE HealthCare Technologies (NASDAQ:GEHC) Stock Price - MarketBeat, https://www.marketbeat.com/instant-alerts/btig-research-issues-pessimistic-forecast-for-ge-healthcare-technologies-nasdaqgehc-stock-price-2026-04-29/
- GE HealthCare Technologies Inc. Stock Price: Quote, Forecast, Splits & News (GEHC) - Perplexity, https://www.perplexity.ai/finance/GEHC?comparing=GEHC,DXCM,JNJ,ZBH,ABT,STE
- GEHC Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/gehc/forecast-price-target
- GE HealthCare forecasts 2026 profit above estimates on strong demand for medical devices, https://www.investing.com/news/stock-market-news/ge-healthcare-forecasts-2026-profit-above-estimates-on-strong-demand-for-medical-devices-4484497
- GE HealthCare: First Patient Dosed in Trial for Manganese-based MRI Contrast Agent, https://www.itnonline.com/content/ge-healthcare-first-patient-dosed-trial-manganese-based-mri-contrast-agent
- NCT07472491 | A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT07472491
- GE HealthCare Technologies (GEHC) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/GEHC/forecast/
- GEHC: GE HealthCare Technologies Inc. - Detailed Earnings Estimates - Zacks.com, https://www.zacks.com/stock/quote/GEHC/detailed-earning-estimates
- Medical Imaging Market Size, Share | Growth Analysis [2034] - Fortune Business Insights, https://www.fortunebusinessinsights.com/industry-reports/medical-imaging-equipment-market-100382
- GE HealthCare Technologies Inc. (GEHC) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/management
- 2026 GE Healthcare Technologies Proxy Statement, https://investor.gehealthcare.com/static-files/50403530-1afa-4794-afdd-502130c06019
- GEHC Technical Analysis for GE Healthcare Technologies Stock - Barchart.com, https://www.barchart.com/stocks/quotes/GEHC/technical-analysis
- GEHC - GE Healthcare Technologies Stock Price - Barchart.com, https://www.barchart.com/stocks/quotes/GEHC